As reported in Pharmaceutical Business Review, Japanese pharmaceutical company Daiichi Sankyo has formed an alliance with Merck and Pfizer to evaluate the combination of its DS-8201  [fam-] (trastuzumab deruxtecan) with avelumab and/or an investigational damage...